Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell–Depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease  by van Burik, Jo-Anne H. et al.
Biology of Blood and Marrow Transplantation 13:1487-1498 (2007)
Q 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1312-0001$32.00/0
doi:10.1016/j.bbmt.2007.08.049Higher Risk of Cytomegalovirus and Aspergillus
Infections in Recipients of T Cell–Depleted Unrelated
Bone Marrow: Analysis of Infectious Complications in
Patients Treated with T Cell Depletion Versus
Immunosuppressive Therapy to Prevent
Graft-versus-Host Disease
Jo-Anne H. van Burik,a Shelly L. Carter,b Alison G. Freifeld,c Kevin P. High,d Kamar T. Godder,e
Genovefa A. Papanicolaou,f Adam M. Mendizabal,b John E. Wagner,a Saul Yanovich,g Nancy A. Kernanf
aDepartments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota; bThe EMMES
Corporation, Rockville, Maryland; cDepartment of Medicine, University of Nebraska, Omaha, Nebraska; dDepartment
of Medicine, Wake Forest University, Winston-Salem, North Carolina; eDepartment of Pediatrics, Virginia
Commonwealth University, Richmond, Virginia; fDepartments of Medicine and Pediatrics, Memorial-Sloan Kettering
Cancer Center, New York, New York; and gDepartment of Medicine, Medical College of Virginia, Richmond, Virginia
Correspondence and reprint requests: Jo-Anne van Burik,MMC250, 420Delaware Street SE,Minneapolis, MN, 55455;
Tel: 612- 625-8462; Fax: 612-625-4410 (e-mail: vanbu004@umn.edu).
Received July 17, 2007; accepted August 30, 2007
ABSTRACT
Serious infections are amajor obstacle limiting the usefulness of unrelated donormarrow transplantation.Graft-
versus-host disease (GVHD) and its therapy are associated with a high risk of opportunistic infection. In this
study, patients were randomized to receive 1 of 2 GVHD prophylaxis strategies, marrow T cell depletion, and
cyclosporine (TCD) or methotrexate/cyclosporine (M/C) after transplantation. The patients underwent trans-
plantation betweenMarch 1995 andOctober 2000 as part of amulticenter randomized trial. As a secondary anal-
ysis, we analyzed infections in this study cohort. Among the 404 patients who underwent transplantation, a total
of 1598 infectionswere reported. The rates of serious and fatal infections did not differ between theTCDandM/
C groups. Bacterial infections accounted for 1/3 of serious infections in each treatment arm. A significantly
higher incidence of severe cytomegalovirus (CMV) and life-threatening or fatal aspergillus infections was ob-
served in the patients receiving TCD (CMV, 28% vs 17% [P 5 .02]; aspergillosis, 16% vs 7% [P\ .01]). The
only independent risk factor for serious infection was the development of grade III-IV acute GVHD (aGVHD;
hazard ratio5 1.41; 95% confidence interval5 1.03-1.91). Strategies to speed immune recovery, even in the ab-
sence of GVHD, are needed to overcome the risk of infection after unrelated donor transplantation.
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Allogeneic bone marrow (BM) and peripheral
blood stemcell (PBSC) transplantation is often compli-
cated by graft-versus-host disease (GVHD) [1]. Be-
cause T cell depletion of the allogeneic donor
product may result in a lower incidence of GVHD
[2], it has been hypothesized that this would be accom-
panied by attendant decreases in infectious complica-tions and increased survival. In the Unrelated Donor
Marrow Transplantation Trial, recipients were
randomized to receive either unmodified marrow
and methotrexate/cyclosporine A immunosuppression
(M/C arm) or ex vivo T cell–depleted marrow and cy-
closporine A (TCD arm) for GVHD prophylaxis [3].
This large, multicenter trial found comparable 3-year
disease-free survival (DFS) between the 2 treatment1487
1488 J.-A. H. van Burik et al.arms despite the more rapid neutrophil recovery, less
acute GVHD (aGVHD), and lower incidence of early
toxicity in the TCD arm. The purpose of this second-
ary analysis was to identify the incidence and types of
infections occurring with each method of GVHD pro-
phylaxis (TCD and M/C) and to determine whether
a reduction in GVHD by TCD was associated with
fewer severe, life-threatening, or fatal infections.
METHODS
Patients
Details on the treatment schemes, including the 2
methods of T cell depletion used in the TCD arm,
have been reported previously [3-5]. In brief, 201 pa-
tients under going transplantation received TCD and
203 received unmodifiedmarrow withM/C. Key base-
line characteristics, except for cell dose infused, were
similar in the 2 treatment arms (Table 1). Accrual oc-
curred between March 1995 and October 2000, with
median follow-up of 4.2 years (range, 2-7 years).
Infection Prophylaxis
In the 15 participating transplantation centers, in-
fectionprophylaxis included local guidelines for preven-
tion of sepsis with viridans streptococci, Pneumocystis
pneumonia, cytomegalovirus (CMV) reactivation,
and fungal infection early after transplantation. In ad-
dition, prophylaxis for encapsulatedGram-positive or-
ganisms was provided for all patients treated for
GVHD [6]. During periods of neutropenia, broad-
spectrum antibiotics were administered for fever. Anti-
fungal agents were augmented to include coverage of
molds duringperiods of persistent fever. Blood product
handling was adjusted for CMV serostatus in accor-
dance with the standards of care of the individual
centers. Patients were hospitalized in single reverse-
isolation rooms, most of which were ventilated with
high-efficiency particulate air filtration systems.
Treatment of Infection
Documented infections were managed by medical
staff according to local standard practice at each of the
participating centers. No specific guidelines were pro-
vided by the study regarding management of estab-
lished infections.
Definition of Infection
Infections starting from the day ofmarrow infusion
(day 0) were reported by the participating centers ac-
cording to predefined criteria (Appendix A). An auditor
checked the information against microbiology, virol-
ogy, imaging, and surgical pathology reports in the
charts. We followed standard definitions of infections
for end-organ sites involving the various bacterial, vi-
ral, and fungal organisms to verify the presence of the
reported infections. Notably, CMV infections thatwere treated with intravenous ganciclovir had a mini-
mum severity of ‘‘severe.’’ Lower respiratory tract viral
infections (including herpes and respiratory viruses)
were documented by the recovery of the organism in
a specimen from the deep pulmonary tree through
such techniques as bronchoscopy or biopsy.
Data Analysis
Data collection forms, infection recurrence inter-
vals, and a data summary from this trial are available
at http://spitfire.emmes.com/study/tcd. The medical
coordinating center (EMMESCorporation, Rockville,
MD) prepared an infection summary for each patient
listing the date, site, organism, and severity of each in-
fection as reported by the primary transplantation cen-
ter. Infections were analyzed by an expert panel review
coupled with a computer algorithm. The panel con-
sisted of 3 bone marrow transplantation (BMT) physi-
cians and 3 infectious disease specialists with expertise
in oncology infections (from5of the participating insti-
tutions), alongwith a statistician. The panel considered
‘‘mild’’ infections to be insignificant for this analysis.
Standardization of Infection Severity Scoring
Classifications of infection severity included ‘‘fa-
tal’’ (ie, present at death or contributing significantly
to death), ‘‘life-threatening’’ (eg, therapy complicated
by hypotension or another event considered life-
threatening), and ‘‘severe’’ (eg, treatment requiring in-
travenous antibiotics). Infections were coded either as
disseminated or by body site. Notably, CMV recov-
ered in the bloodstream only (by either antigenemia
or DNA testing) was not considered disseminated.
‘‘Serious’’ refers to the grouping of severe, life-threat-
ening, and fatal infections.
An algorithm was developed using SAS version 8.2
(SAS Institute, Cary,NC) to apply ‘‘rules’’ for interpre-
tation of raw culture data in a set sequence. First, the
algorithm distinguished contiguous sites (Appendix
B) from noncontiguous sites of infection and deter-
mined whether to score the infection episode as ‘‘dis-
seminated’’ or not, if the transplantation center had
not already specified a disseminated designation. A dis-
seminated status was assigned if the raw culture data
indicated that the same organism was present at 2 or
more noncontiguous sites on the same day. ‘‘Not
otherwise identified’’ (NOI) infectious organisms and
episodes with mild severity were not categorized as
disseminated. Although disseminated infections were
categorized and tallied by the algorithm, individual in-
fection episodes retained their original site codes on
the summary reports for panel review so that the panel
could subsequently confirm the disseminated designa-
tion, as well as the final tally of disseminated infections
as computed by the algorithm.
Second, the transplantation center–generated
severity score was upgraded to life-threatening for
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TCD arm M/C arm Total
Characteristic n % n % n % P
Recipient age
\18 years 47 23% 49 24% 96 23% .93
18-34 years 68 34% 72 35% 140 34%
.35 years 88 43% 86 42% 174 42%
Recipient sex
Male 113 56% 110 53% 223 55% .65
Recipient ethnicity
White 168 83% 171 83% 339 83% .98
Hispanic 12 6% 10 5% 22 5%
African American 15 7% 17 8% 32 8%
Asian 3 1% 3 1% 6 1%
Other (mixed or missing) 5 3% 6 3% 11 3%
Recipient performance status (Karnofsky score)
100% 78 38% 63 30% 141 34% .17
80% and 90% 114 56% 135 65% 249 61%
70% 11 5% 9 4% 20 5%
Recipient disease/disease stage
Chronic myelogenous leukemia
(n 5 21 in accelerated phase/blast crisis)
94 46% 88 42% 182 44%
Acute myelocytic leukemia 49 24% 54 26% 103 25%
Acute lymphocytic leukemia 42 20% 46 23% 89 21%
Myelodysplastic syndrome 12 6% 11 5% 23 6%
Other leukemia 6 3% 5 2% 11 3%
Non-Hodgkin lymphoma 0 0% 3 1% 3 1%
Donor/recipient CMV serostatus
Positive/positive 40 20% 33 16% 73 18% .70
Positive/negative 30 15% 39 19% 69 17%
Negative/positive 54 27% 51 25% 105 26%
Negative/negative 72 35% 75 36% 147 36%
Unknown 7 3% 9 4% 16 4%
Donor/recipient HLA match*
A, B, and DRB1 match 146 72% 152 73% 298 73% .73
A mismatch 19 9% 21 10% 40 10%
B mismatch 21 10% 15 7% 36 9%
DRB1 mismatch 17 8% 19 9% 36 9%
Method of T-cell depletion
Elutriation center† 67 33% 71 34%
Monoclonal antibody center‡ 136 67% 136 66%
*HLA A/B matching determined serologically; DRB1, high resolution.
†A physical method of separating T cells from hematopoietic stem and progenitor cells, counterflow centrifugal elutriation (BeckmanCorp, Palo
Alto, CA).
‡An antibodymethod of targeting the ab subunit of the T cell receptor and lysing bound cells in the presence of rabbit complement using mono-
clonal antibody T10B9 (MEDI-500; Medimmune Corp, Gaithersburg, MD).specific infections within the lower airway (ie, CMV,
molds, respiratory viruses [eg, respiratory syncytial vi-
rus, influenza, and parainfluenza], and Pneumocystis),
within the central nervous system (ie, human herpesvi-
rus-6, Aspergillus, and Toxoplasma), or disseminated (ie,
CMV, Aspergillus, and Toxoplasma). If 2 infections were
reported on the same day with the same organism at
contiguous sites, only the maximum severity score
was counted. The algorithm upgraded to life-threaten-
ing in 23% of the transplantation center–reported dis-
seminated or pulmonary CMV infection episodes,
62% of respiratory virus infection episodes, 20% of
disseminated or pulmonary aspergillosis episodes,
and 25% of pulmonary pneumocystosis episodes.The number of patients affected by these infection
episode upgrades was similar to the percentage of
infection episodes upgraded and was similar in the 2
treatment arms.
Third, the algorithm counted and calculated the
maximum severity of infections. The algorithm con-
sidered the organism and site to determine whether
multiple reports represented the same infection based
on recurrence intervals specific to each organism. If
multiple episodes with the same organism occurred
within a recurrence interval (Appendix C), then the
starting date of the infection was taken to be the date
of the first occurrence of the infection, and the severity
of the episode was the maximum severity over the
1490 J.-A. H. van Burik et al.recurrence interval. Finally, the number of infections
was tallied.
Statistical Analysis
Categorical risk factors were compared using the
c2 statistic, whereas continuous variables were ana-
lyzed using the t-test procedure. All data on time to
failure were calculated from the date of BMT to the
date of the event. Infectious episodes were censored
at time of relapse or primary or secondary graft failure,
or as of April 2002. Time-to-failure analyses were per-
formed using the cause-specific failure probability
method, with death treated as a competing risk and
censored at the date of last contact [7]. The probability
of survival was estimated by the Kaplan-Meier method
[8], and the log-rank test was used for univariate com-
parisons [9]. Variables considered included randomi-
zation arm, cell doses, baseline demographics for
recipient and donor, disease status, risk status, HLA
match, recipient CMV status, time to engraftment
(time-dependent), time to maximum aGVHD grade
III-IV (time-dependent), and time to chronic GVHD
(aGVHD; time-dependent). Covariates with a P value
\ .10 were considered in a Cox proportional hazards
model with time-dependent variables [10]. A forward-
stepwise selection procedure was implemented with
a type I error of .05. All analyses were performed using
the SAS software.
RESULTS
Infection Incidence and Severity
A total of 1598 infection events were reported in
404 patients, of which 80% were severe, 10% were
life-threatening, and 10% were fatal. Of the bacterial
infections experienced by these patients, the majority
were serious (74%); of the viral infections 48% were
serious, and of the fungal infections, 31%were serious.
The overall incidence of infection did not differ
significantly by treatment arm; a total of 885 infection
episodes were reported in the 182 TCD patients, first
occurring at a median of 17 days after transplantation,
versus 713 in 171M/C patients, first occurring at a me-
dian of 20 days after transplantation (P 5 .06). How-
ever, the prevalence of severe infection was higher in
the TCD arm (170 of 201 with at least 1 severe infec-
tion [85%] vs 153 of 203 [75%]; P 5 .02). The fre-
quency of severe infections per patient was also
higher in the TCD arm (. 5 infections vs 1-5 infec-
tions; P 5 .06; Table 2), although the time to first se-
vere infection was similar in the 2 arms (P 5 .14;
Figure 1A).
Serious bacterial infections were equally prevalent
in both arms (Table 2) and did not adversely affect sur-
vival (Figure 1B). Serious viral infections were more
frequent in the TCD arm (55% vs 41%; P 5 .005),
as reflected by more severe (although not more life-threatening or fatal) infections. The patients in the
TCD arm were at greater risk for development of a se-
rious fungal infection (38% vs 24%; P 5 .002) and
were at particularly greater risk of developing a life-
threatening or fatal aspergillus infection (15% vs 7%;
P 5 .011).
The prevalence of serious polymicrobic infections
was not significantly different in the 2 arms (23% in the
TCD arm vs 28% in the M/C arm; P 5 .28). The in-
cidence of polyorganism infections as a primary cause
of death was not significantly different in the 2 arms
(4% in the TCD arm vs 1% in the M/C arm), but
the incidence of polyorganism infections contributing
to death (taken as either a primary or secondary cause
of death) did differ (13% vs 4%; P 5 .007).
Disseminated Infections
Among the entire study group, 73 patients had 83
disseminated infection events caused by 122 organ-
isms. Bacterial pathogens included both Gram-nega-
tive and Gram-positive organisms and occurred in
6%of the patient population. CMVwas themost com-
mon herpesvirus causing disseminated infection, man-
ifested primarily as viremia (CMV recovered from
blood by either antigenemia and/or DNA) with pul-
monary involvement. Among disseminated fungal
pathogens, mold infections were more common than
yeast infections (79% vs 21% of fungal pathogens),
with no differences between the TCD and M/C arms
(P 5 .30).
Bacterial Bloodstream Infections
The probability of developing a serious bacterial
bloodstream infection was not different between the
TCD andM/C arms, with 60% of all enrolled patients
developing bacteremia (P 5 .13; Figure 1C). Coagu-
lase-negative Staphylococcus was the leading cause of
the bloodstream infections (n 5 242; 40%), followed
by Enterococcus (n5 58), Streptococcus (n5 37), Klebsiella
(n5 33),Pseudomonas (n5 25),Staphylococcus aureus (n5
25), Enterobacter (n5 23),Acinetobacter (n5 13), Escher-
ichia coli (n 5 13), Citrobacter (n 5 12), Corynebacterium
(diphtheroids) (n5 12),Bacillus (n5 10),Stenotrophomo-
nas (n5 9), and others (n5 72).
Bacterial Infections
When examining associations between bacterial
organisms grouped according to microbiology classes
(ie, aerobic Gram-positive, aerobic Gram-negative,
anaerobic, and other/mycobacterium), more aerobic
Gram-positive infections (especially coagulase-nega-
tive Staphylococcus) were noted in the TCD arm (P 5
.05). However, there was no difference in serious or
disseminated Gram-positive or Gram-negative infec-
tions between the 2 arms.
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TCD arm (n 5 201) M/C arm (n 5 203) Total (n 5 404)
n % n % n % P
Bacterial .34
‘‘Serious’’ infections per patient 153 76% 146 72% 299 74%
Severe 117 58% 112 55% 229 57%
Life-threatening 16 8% 13 6% 29 7%
Fatal 20 10% 21 10% 41 10%
Viral .005
‘‘Serious’’ infections per patient 110 55% 83 41% 193 48%
Severe 59 29% 41 20% 100 25%
Life-threatening 31 15% 26 13% 57 14%
Fatal 20 10% 16 8% 36 9%
Fungal .002
‘‘Serious’’ infections per patient 76 38% 48 24% 124 31%
Severe 31 15% 28 14% 59 15%
Life-threatening 12 6% 4 2% 16 4%
Fatal 33 16% 16 8% 49 12%
Infection rates
Polymicrobial infections per patient 47 23% 57 28% 104 26% .28
Bloodstream infection episodes .05
Bacterial infections 309 275 584 .05
Aerobic Gram-positive 224 174 398
Aerobic Gram-negative 66 87 153
Anaerobic 9 7 16
Other bacteria 10 7 17
Bacterial episodes 279 234 513
Number of patients with bacterial
infections
128 64% 115 57% 243 60%
CMV 61 34 95
Candida (C. albicans, n 5 6) 8 10 18
Bacterial/viral/fungal organisms 384 325 707
Bacterial/viral/fungal episodes 351 282 633
Patients with any bloodstream
infection
144 72% 128 63% 272 67%
Non-bloodstream infections
Bacterial organisms 304 235 539
Bacterial infection episodes 238 186 424
Patients with bacterial infections 48 24% 54 27% 102 25%
Viral organisms 117 102 219
Viral episodes 115 96 211
Patients with viral infections 62 31% 53 26% 115 28%
Fungal organisms 96 67 163
Fungal episodes 84 58 142
Patients with fungal infections 51 25% 39 19% 90 22%
Bacterial, viral, and fungal infections are patient-based and listed bymaximum severity. Bloodstream and non-bloodstream infections are listed as
total episodes.aGVHD grade III-IV (hazard rate [HR] 5 1.35;
[95% confidence interval [CI] 5 1.00-1.82; P 5 .05)
and chronic GVHD (HR 5 1.96; 95% CI 5 1.14-
3.36; P 5 .01) were significantly associated with the
incidence of bacterial infection, with no significant dif-
ference between the 2 treatment arms.
There were 49 disseminated bacterial infections
(Pseudomonas [n 5 13], Klebsiella [n 5 9], Streptococcus
[n 5 7], Staphylococcus aureus [n 5 6], coagulase-nega-
tive Staphylococcus [n 5 4], E. coli [n 5 4], Enterobacter
[n 5 2], and Enterococcus [n 5 4]), leading to 26 infec-
tion episodes in 23 of the 404 patients (6%).Localized Infections
Serious localized infections (not bloodstream and
not disseminated) included 424 bacterial, 211 viral,
and 142 fungal infections (Table 2). The lower airway
accounted for 91 bacterial, 44 viral, and 63 fungal in-
fection episodes. Clostridium difficile accounted for 34
infection episodes. Catheters, catheter tips, and
wounds accounted for 88 infection episodes, the geni-
tourinary tract accounted for 88 bacterial infection ep-
isodes, and dermatomal zoster accounted for 39
infection episodes.
1492 J.-A. H. van Burik et al.Figure 1. Serious infections. A, Time to developing a serious infection (severe, life-threatening, or fatal) was similar in the 2
treatment arms over the 3-year follow-up period (P5 .14). B, Survival by treatment and presence of a serious bacterial in-
fection (P5 not significant). C, Probability of developing a serious bacterial bloodstream infection (severe, life-threatening,
or fatal) in the first year posttransplantation was similar in the 2 treatment arms (P 5 .13).
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CMV caused 23 disseminated infections, 95 vire-
mias, 12 upper respiratory tract infections, 14 lower re-
spiratory tract infections, 1 episode of enteritis, and 2
episodes of retinitis (Table 3). By 1 year after transplan-
tation, the probability of developing a serious CMV in-
fection was higher in the TCD arm (28%) than the M/
C arm (17%) (P5 .02; Figure 2A). Three-year survival
for patients with at least 1 serious CMV infection was
26% in the TCD arm and 43% in the M/C arm (P 5
.09; Figure 2B). Among the CMV-seropositive recipi-
ents, the reactivation rate was 53% in the TCD arm
and 33% in theM/C arm (P5 .04; Figure 2C). Among
CMV-seronegative recipients, the primary infection
rate was 5% in the TCD arm and 4% in the M/C arm.
The multivariate model found a significantly in-
creased risk of a serious CMV infection for TCD treat-
ment (P5 .03), recipient positive CMV serostatus (P\
.01), and female recipients (P 5 .02) (Table 4). GVHD
wasnot associatedwith seriousCMV. In themultivariate
model, TCD treatment was associated with more fre-
quent serious viral infections (P5 .01), recipient positive
CMV serostatus (P\ .01), and cGVHD (P\ .01).
Herpes simplex caused 4 disseminated infections, 1
central nervous system infection, 29 upper respiratory
tract infections, 4 lower respiratory tract infections
(with 3 dying on days 35, 88, and 94 posttrans-
plantation, and 1 living to last follow-up at day 2370
posttransplantation), 2 episodes of female pelvic infec-
tion, 11 episodes of localized skin infection, and 1
episode of genitourinary infection. There were 6 dis-
seminated and 39 localized zoster skin infections,
with no difference in the distribution of these viral in-
fections in the 2 treatment arms. The sample size was
too small to allow evaluation of risk factors.
Adenovirus caused 3 disseminated infections, 5 up-
per respiratory tract infections, and 1 episode of (seri-
ous) urinary infection. Respiratory viruses caused 49
upper respiratory tract infections and 24 lower respira-
tory tract infections.
Fungal Infections
Serious fungal infections were more frequent in
the TCD arm (38% vs 24%; P\ .01), adversely im-
Table 3. CMV infections (severe, life-threatening, fatal) by site
Site
TCD arm
(n 5 201)
M/C arm
(n 5 203)
Total
(n 5 404)
Contiguous site 2 5 7 12
Contiguous site 3 9 5 14
Contiguous site 4 0 1 1
Contiguous site 9 3 0 3
Contiguous site 10 61 34 95
Disseminated 16 7 23
Eyes 2 0 2
See definitions of the contiguous groups in Appendix B.pacting survival (Figure 3A). The probability of devel-
oping aspergillosis by 3 years posttransplantation
reached 16% in the TCD arm compared with 7% in
the M/C arm (P\ .01; Figure 3B). Occurrence of se-
rious aspergillosis had a bimodal property, with peak
occurrence either during the first 2 months or later
posttransplantation (data not shown).
Episodes of disseminated infection were caused by
Aspergillus-like molds in 26 cases, zygomycetes in 2
cases, andyeast in7 cases (Candidakrusei [n53],Candida
albicans [n 5 1], Candida parapsilosis [n 5 1], Candida/
Torulopsis glabrata [n5 1], yeast [not otherwise specified,
n 5 1]), with no differences between the TCD and
M/C arms (P 5 .30). Episodes of fungemia included
C. albicans (6 cases), C. krusei (3 cases), C. parapsilosis
(3 cases), C. glabrata (3 cases), and C. tropicalis (1 case).
As shown in Table 4, marrow TCD (HR 5 1.79;
95% CI 5 1.24-2.59; P\ .01), aGVHD grade III-IV
(HR 5 2.06; 95% CI 5 1.32-3.24; P\ .01), cGVHD
(HR5 2.03; 95% CI5 1.14-3.60; P5 .02), and older
recipients (HR 1.01; 95% CI 5 1.00-1.03; P 5 .03)
were associated with higher risk of a serious fungal in-
fection. Serious Aspergillus infections were associated
with similar findings (Table 4).
Neutropenia
Serious infection occurred in 78% of patients who
did not engraft by day 42 posttransplantation, com-
pared with 62% of the patients who did engraft during
this period (P 5 .06).
Late Infections
In the multivariate model of time to Aspergillus in-
fection, the risk of GVHD was significant. When ad-
justing for GVHD in the Aspergillus model, the TCD
patients had a higher risk of Aspergillus infection.
The risk of GVHDwas not significant in the multivar-
iate model of time to CMV infection.
DISCUSSION
This study represents the largest randomized trial
to date in unrelated donor BMT with prospective col-
lection of all infection events in 2 treatment arms with
3-years of follow-up [3]. Although the primary objec-
tive was to determine the difference in survival be-
tween 2 methods of GVHD prophylaxis (TCD and
M/C) [3,11], it was hypothesized that reduction of
GVHD by TCD would result in a concomitantly
lower risk of opportunistic infection, which is the sin-
gle most important barrier to successful BMT [12-15].
The strengths of this prospective study are the large
sample size and detailed data capture on all infections
during extended follow-up.
The results of this study illuminate several obser-
vations regarding infections in recipients of unrelated
1494 J.-A. H. van Burik et al.Figure 2.CMV. A, The probability of developing a serious CMV infection (severe, life-threatening, or fatal) was higher in
the TCD arm (28%) compared with the M/C arm (17%) (P5 .02). B, Three-year survival in patients who developed a se-
rious CMV infection was 26% in the TCD arm versus 43% in the M/C arm (P 5 .09). C, Among CMV-seropositive re-
cipients, the likelihood of developing a serious CMV infection was higher in the TCD arm (0.53) compared with the M/C
arm (0.33) (P 5 .04).partially T cell–depleted marrow. First, bacteria were
cultured from the bloodstream in 2/3 of patients and
accounted for 1/3 of the serious infections in each
treatment arm. Second, the likelihood of developing
a severe CMV infection was higher in the TCD arm.Third, the probability of developing a life-threatening
or fatal mold infection was higher in the TCD arm.
Finally, TCD depletion, maximum aGVHD score of
grade III or IV, previous cGVHD, primary underlying
diseases that were not chronic myelogenous leukemia,
Infections in Unrelated Transplantation 1495Table 4. Prognostic factors associated with time to infection
HR 95% CI P Favorable factors
Time to first serious infection
Treatment 1.28 1.04-1.59 .023 Methotrexate/cyclosporine
Acute GVHD 1.41 1.03-1.91 .030 Acute GVHD grade 0-II
Chronic GVHD 1.97 1.24-3.12 .004 No chronic GVHD
Primary disease 1.27 1.02-1.57 .030 Chronic myelogenous leukemia
Neutropenia 0.40 0.21-0.73 .003 Early engraftment
Time to first serious bacterial infection
Treatment 1.20 0.95-1.51 .130 Not significant
Acute GVHD 1.35 1.00-1.82 .051 Acute GVHD grade 0-II
Chronic GVHD 1.96 1.14-3.36 .014 No chronic GVHD
Time to first serious viral infection
Treatment 1.44 1.08-1.92 .01 Methotrexate/cyclosporine
Recipient CMV Serostatus 2.38 1.78-3.19 \ .01 Recipient negative CMV serostatus
Chronic GVHD 2.33 1.42-3.82 \ .01 No chronic GVHD
Time to first serious CMV infection
Treatment 1.57 1.04-2.39 .034 Methotrexate/cyclosporine
Recipient CMV Serostatus 12.63 6.70-23.82 \ .01 Recipient negative CMV serostatus
Recipient sex 1.61 1.07-2.44 .024 Male recipients
Time to first serious fungal infection
Treatment 1.79 1.24-2.59 \ .01 Methotrexate/cyclosporine
Acute GVHD 2.06 1.32-3.24 \ .01 Acute GVHD grade 0-II
Chronic GVHD 2.03 1.14-3.60 .016 No chronic GVHD
Recipient age 1.01 1.00-1.03 .031 Younger recipients
Time to first serious Aspergillus infection
Treatment 2.51 1.41-4.49 \ .01 Methotrexate/cyclosporine
Acute GVHD 3.27 1.75-6.10 \ .01 Acute GVHD grade 0-II
Chronic GVHD 2.94 1.18-7.32 .021 No chronic GVHD
Recipient age 1.02 1.00-1.04 .022 Younger recipients
NOTE: Variables considered for the multivariate analysis included treatment arm, total nucleated cell dose per kg, T cells per kg, and CD34
dose per kg, TCD method (elutriation vs T10B9 monoclonal antibody), all variables in the demographics table, donor characteristics,
disease, risk status, HLA match, recipient CMV status, infection episode, time to engraftment (time-dependent), time to maximum acute
GVHD grade (time-dependent), and time to chronic GVHD (time-dependent).and time to engraftment were independent predictors
of time to occurrence of the maximum severe infec-
tion.
Comparing infections occurring in the 2 treatment
arms found no difference in time to occurrence of bac-
terial infections of maximum severity. In this study, as
in other data assessments after hematopoietic stem cell
transplantation (HSCT) [16], bacteremia was a com-
mon complication. A study evaluating infections
occurring between 1982 and 2001 found 0.65 bacter-
emic episodes per patient, involving coagulase-nega-
tive staphylococci (42%), Gram-negative bacteria
(32%), streptococci (12%), other Gram-positive bac-
teria (8%), and anaerobes (2%) [17]. Bacteremias
were more frequent in allogeneic transplantations
(0.96 episode/patient) compared with autologous
transplantations (0.44) (P \ .0001); 53% occurred
before hospital discharge, and 47% occurred after
discharge [17]. Bloodstream infections have been inde-
pendently associated with hospital-related mortality in
HSCT recipients [18].
Prevention of CMV infection is an integral com-
ponent of transplantation surveillance, necessitating
prompt initiation of preemptive therapy to preventend-organ disease [13]. Preemptive surveillance and
treatment strategies were roughly equivalent among
the various participating centers; the dependence
on local strategies is a limitation of this study. Our
data demonstrate a greater likelihood of CMV reac-
tivation in CMV-seropositive recipients in the TCD
arm compared with the M/C arm. The time to onset
and the severity of CMV did not differ between the
2 treatment arms. This study verifies the striking
association between recipient CMV seropositivity
and the likelihood of subsequent CMV infection, re-
gardless of the method of GVHD prophylaxis used
[19]. Primary CMV infection was infrequent and oc-
curred at a similar rate in the 2 treatment arms
among patients who were CMV-seronegative before
transplantation.
Serious fungal infections were more frequent in
the TCD arm. In this study, the frequency of infection
by Candida species was low, and the frequency of mold
infections was higher [20-22]. Our study demonstrates
the bimodal property of invasive aspergillosis after
transplantation, a condition known to have separate
risk factors accounting for early and later infection
peaks [23].
1496 J.-A. H. van Burik et al.Because themethods ofT cell depletion in this clin-
ical trial were onlymoderately extensive, yielding a 1 to
2 log10 depletion of CD31T cells, the patients needed
additionalGVHDprophylaxis (with cyclosporine). It is
not known whether the resulting rate of infection
Figure 3.Aspergillosis. A, Survival by treatment and presence of a se-
rious fungal infection. B, The likelihood of developing aspergillosis
(life-threatening or fatal) by 3 years posttransplantation was greater
in the TCD arm (0.16) compared with theM/C arm (0.07) (P\ .01).would be similar in a setting with more complete
TCD (3 to 4 log10 depletion), in which posttransplan-
tation immunoprophylaxis was not required. Extensive
TCD is possible with newer monoclonal antibodies
(mAbs) such as alemtuzumab; studies of this compound
have demonstrated a very high rate of CMV and fungal
infection [24], necessitating aggressive prophylaxis
regimens to reduce the risk of serious infection [25].
This demonstrates that the high risks of CMV and
mold infection demonstrated in this study with modest
TCD methods are likely to persist, or even increase,
with the use ofmore aggressiveTCDregimens, despite
a reduced need for additional immunosuppression and
lower rates of GVHD.
The TCD recipients exhibited more infections de-
spite a reduction in the standard risk factors of infec-
tion—namely, less GVHD and faster neutrophil
recovery. This inverse relationship between GVHD
and infection was an unexpected finding. Infections
were censored by relapse and graft failure, so that dif-
ferences between the 2 randomized groups resulted
from the treatment strategy.
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1498 J.-A. H. van Burik et al.APPENDIX A: INFECTION GRADING CRITERIA
Severity grading
Fatal Present at death or contributed significantly to death
Life-threatening* Complicated by hypotension or other event considered life-threatening
Severe Treatment required intravenous antibiotics
Moderate Oral treatment
Mild No treatment
Infection categories
Serious Infections grouped as severe, life-threatening, or fatal
Disseminated An infection that appeared to be generalized or if the organism was isolated at 2 or more distinct
sites within 24 hours
Polymicrobic More than 1 organism was cultured from the same body site on the same day within the same
organism category (bacterial, fungal, or viral)
Polyorganism More than 1 pathogen from different organism categories was causing or contributing to an
infection at the time of death
*The review panel upgraded transplantation center–assigned severity designation to life-threatening for the following nonbacterial infections:
CMV (within contiguous group 3 [lower airway] or disseminated); respiratory viruses (respiratory syncytial virus, influenza, and parainfluenza
within contiguous group 3); human herpesvirus-6 (within contiguous group 1 [central nervous system (CNS)]); molds (within contiguous
group 3 or respiratory tract unspecified);Aspergillus (within contiguous group 1 or when disseminated); Pneumocystis (within contiguous group
3); and Toxoplasma (within contiguous group 1 or when disseminated).
APPENDIX B: CONTIGUOUS BODY SITE DEFINITIONS FOR DISSEMINATED INFECTION
Contiguous groupings
1. CNS: Brain, spinal cord, meninges, spinal fluid
2. Upper airway/gastrointestinal tract: Sinuses, upper airway, respiratory tract unspecified, nasopharynx, laryngitis/larynx, lips, tongue,
oral cavity, oropharynx, mouth, esophagus, stomach, small intestine, large intestine, feces, stool
3. Lower airway: Lower respiratory tract, pleural cavity, pleural fluid
4. Abdominal cavity: Liver, spleen, gallbladder and biliary tree (not hepatitis), pancreas, peritoneum
5. Prostate, testes
6. Fallopian tubes, uterus, cervix, vagina
7. Catheters/catheter tips/wounds: Central venous catheter (not otherwise specified), wound body site, or catheter tip
8. Skin: Skin, genital area skin, rash, pustules, abscess
9. Genitourinary tract: Kidneys, renal pelvis, ureters, bladder
10. Bloodstream: Blood, buffy coat, bone marrow
Special contiguous grouping for respiratory viruses (influenza, RSV, parainfluenza, rhinovirus) and any fungus
Groups 2 and 3 above
Sites of infection not included in any contiguous groupings
Disseminated, eyes, ears, joints, bone cortex (i.e., osteomyelitis),muscle, cardiac (endocardium,myocardium, pericardium), lymph nodes,
other
APPENDIX C: RECURRENCE INTERVALS FOR SPECIFIC ORGANISMS
Recurrence interval Organisms
1 week (# 7 days) All bacterial organisms* other than Clostridium difficile and all mycobacteria
2 weeks (# 14 days) All yeast *, including Candida and Cryptococcus
Varicella-zoster virus
All respiratory viruses, including respiratory syncytial virus, parainfluenza, influenza, and rhinovirus
1 month (# 30 days) Clostridium difficile
Bacterial organisms in contiguous groupings 2 and 3
Yeasts in contiguous groupings 2 and 3
2 months (# 60 days) Polyomavirus
Adenovirus
Enteroviruses
CMV
Herpes simplex virus
3 months (# 90 days) All molds, including Aspergillus, Fusarium, and the agents of zygomycosis
All mycobacteria
1 year (# 365 days) Helicobacter pylori
Nocardia
*Except for those bacterial and yeast organisms with site codes falling in contiguous groups 2 and 3.
